By Emilie Ruscoe ( October 17, 2025, 5:06 PM EDT) -- Sana Biotechnology Inc. has asked a Seattle federal court to dismiss an investor suit over claims that it offered misleading statements regarding early clinical trials of a gene therapy, asserting that the company's disclosures were consistent with early-stage drug development risks....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.